查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2052635

膽管癌（膽道癌）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035）

Cholangiocarcinoma (Bile Duct Cancer) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計到2035年，德國膽管癌市場規模將從約 2億美元成長到 6.8億美元。
  • 推動市場成長的因素如下：
  • 擴大標標靶治療和免疫療法的應用
  • 擴大基於生物標記的治療策略的應用
  • 市場規模的擴大是由高品質的癌症治療以及適用患者群體的擴大所推動的。
  • 未來的成長將取決於精準腫瘤學和下一代標靶治療的進步。

膽管癌（膽道癌）概述

膽管癌（膽管癌）是一種起源於膽管上皮細胞的惡性腫瘤，由慢性膽管炎、FGFR2融合基因、IDH1/2突變和KRAS突變等促進致癌性的因素所引起。膽管癌可分為肝內型、門週型及遠端型。臨床表現為進行性阻塞性黃疸、搔癢、體重減輕和腹痛，其中門週型腫瘤可導致早期膽道阻塞。診斷需結合分子譜分析、MRI/MRCP、CA19-9檢測和組織切片檢查。腫瘤的可切除性取決於血管侵犯和轉移的程度。手術切除是唯一的根治性治療方法，gemcitabine-cisplatin聯合durvalumab是標準的第一線全身治療方案。對於適合接受分子標靶治療的患者，FGFR2和IDH1抑制劑可作為分子標靶治療的選擇。膽道引流可最佳化症狀控制。鑑於整體預後不良，早期整合安寧療護並制定治療目標非常重要。

主要亮點

  • 根據預測，德國膽管癌確診病例將從2025年的約 4,388 例增加到2035年的4,612 例。
  • 膽管癌（CCA）是一種高度侵襲性的膽管惡性腫瘤，預後不良，存活期有限。
  • 疾病確診時往往已發展到晚期，這一事實仍是造成疾病負擔和死亡率的重要因素。
  • 分子譜分析正日益成為標靶治療方法的基礎。
  • 隨著 FGFR 抑制劑、IDH 抑制劑和免疫療法的應用，治療選擇不斷增加。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於MicrosoftExcel）
  • 流行病學資料（MS Excel，互動式工具）
  • 高層洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

主要企業

  • Genfit
  • RedHill Biopharma Limited
  • Eisai Co., Ltd.
  • Incyte Corporation
  • Servier
  • Virogin Biotech Ltd.
  • 3D Medicines（Beijing）Co., Ltd.
  • TransThera Sciences（Nanjing）, Inc.
  • Taiho Oncology, Inc.
  • Boehringer Ingelheim
  • Verismo Therapeutics
  • Hutchmed
  • Medivir
  • Eli Lilly and Company
  • Bold Therapeutics, Inc.
  • Elevar Therapeutics
  • Rigel Pharmaceuticals
  • Compass Therapeutics
  • Toray Industries, Inc.
  • MacroGenics
  • Cogent Biosciences, Inc.
  • Pheast Therapeutics
  • Leap Therapeutics, Inc.
  • Seagen, a wholly owned subsidiary of Pfizer
  • SOFIE
  • TCR2 Therapeutics
  • Alentis Therapeutics AG
  • Elicio Therapeutics
  • Arbele Pty Ltd.
  • Apollo Therapeutics Ltd.
  • Context Therapeutics Inc.
  • Merck Sharp &Dohme LLC
  • Celldex Therapeutics
  • Hoffmann-La Roche

目錄

第1章 主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 依藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法 - 概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章 未滿足的需求與TPP分析

  • 主要未滿足的需求及其未來透過新興治療方法實現的可能性
  • TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

簡介目錄

Cholangiocarcinoma (Bile Duct Cancer) Market Outlook

Thelansis's "Cholangiocarcinoma (Bile Duct Cancer) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cholangiocarcinoma (Bile Duct Cancer) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cholangiocarcinoma (Bile Duct Cancer) Overview

Cholangiocarcinoma is a malignancy arising from biliary epithelial cells, classified as intrahepatic, perihilar, or distal, driven by chronic biliary inflammation, FGFR2 fusions, IDH1/2 mutations, and KRAS alterations promoting oncogenic transformation. It presents with progressive obstructive jaundice, pruritus, weight loss, and abdominal pain, with perihilar tumors causing early biliary obstruction. Diagnosis integrates MRI/MRCP, CA19-9, and tissue biopsy with molecular profiling; vascular involvement and metastatic spread define resectability. Surgical resection remains the only curative option; gemcitabine-cisplatin with durvalumab is the standard first-line systemic regimen. FGFR2 and IDH1 inhibitors provide targeted options in molecularly selected patients. Biliary drainage optimizes symptom control. Early palliative integration and goals-of-care planning are essential given poor overall prognosis.

Key Highlights

  • In Germany, diagnosed cholangiocarcinoma cases are projected to increase from approximately 4,388 in 2025 to 4,612 by 2035.
  • CCA remains an aggressive biliary tract malignancy associated with poor prognosis and limited survival.
  • Late-stage diagnosis continues to contribute to significant disease burden and mortality.
  • Molecular profiling is increasingly enabling targeted treatment approaches.
  • FGFR inhibitors, IDH inhibitors, and immunotherapies are expanding therapeutic options.

Market Overview

  • The Germany cholangiocarcinoma market is projected to grow from approximately $200 MN to $680 MN by 2035.
  • Market growth is supported by:
  • Increasing adoption of targeted therapies and immunotherapy
  • Growing use of biomarker-driven treatment strategies
  • Market value growth is driven by premium oncology therapies and expanding eligible patient populations.
  • Future growth will depend on precision oncology advancements and next-generation targeted treatments.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Genfit
  • RedHill Biopharma Limited
  • Eisai Co., Ltd.
  • Incyte Corporation
  • Servier
  • Virogin Biotech Ltd.
  • 3D Medicines (Beijing) Co., Ltd.
  • TransThera Sciences (Nanjing), Inc.
  • Taiho Oncology, Inc.
  • Boehringer Ingelheim
  • Verismo Therapeutics
  • Hutchmed
  • Medivir
  • Eli Lilly and Company
  • Bold Therapeutics, Inc.
  • Elevar Therapeutics
  • Rigel Pharmaceuticals
  • Compass Therapeutics
  • Toray Industries, Inc.
  • MacroGenics
  • Cogent Biosciences, Inc.
  • Pheast Therapeutics
  • Leap Therapeutics, Inc.
  • Seagen, a wholly owned subsidiary of Pfizer
  • SOFIE
  • TCR2 Therapeutics
  • Alentis Therapeutics AG
  • Elicio Therapeutics
  • Arbele Pty Ltd.
  • Apollo Therapeutics Ltd.
  • Context Therapeutics Inc.
  • Merck Sharp & Dohme LLC
  • Celldex Therapeutics
  • Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)